Identification

Listing sponsor / Agent
Degroof Petercam SA/NV
Symbol
ONWD
ISIN code
NL0015000HT4
Code LEI
9845007A2CC4C8BFSB80
Exchange / Market
Euronext
Trading location
Amsterdam
Brussels
Capitalization compartment
Compartment B
ICB
20101025 Health Services
Website address
https://www.onwd.com

Operation

IPO date
Qui 21/10/2021
IPO price
EUR 12.75
IPO type
Initial Public offering
Dual listing
Operation calendar

Market of reference is Brussels

Price range
EUR 11.75 - EUR 13.75

Perfil da Empresa

Onward Medical N.V. is a medical technology company developing and commercializing innovative therapies to enable functional recovery for people with spinal cord injury and movement disabilities.

Fonte: Cofisem - Última atualização: 04 Nov 2024
Principais Executivos
Chief Executive Officer Dave Marver
Director People & Culture Julie Crom
Vice President Engineering Julien Camisani
Vice President Global Clinical, Regulatory & Quality Erika Ross Ellison
Vice President Global Marketing Sarah Moore
Vice President Operations Robert Odell
Vice President Legal Lorenzo Fanti
Finance Director Amori Fraser
Head of Strategy & Corporate Development Alexandre Casteau
Fonte: Onward Medical N.V. - Última atualização: 24 Sep 2024
Números principais
Millenium 2023 2022 2021 2020 2019
Net sales 532 2.148 1.399 800 554
Income from ordinary activities 532 2.148 1.399 800 554
Operating income -35.463 -32.028 -28.532 -15.512 -10.772
Cost of financial indebtedness net 421 1.453 5.613 4.441 2.670
Equity-accounted companies contribution to income
Net profit from discontinued activities
Net income -36.181 -32.772 -34.314 -20.014 -13.483
Net income (Group share) -36.181 -32.772 -34.314 -20.014 -13.483
Fiscal year end 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards IFRS IFRS IFRS IFRS IFRS
Fonte: Cofisem - Última atualização: 04 Nov 2024
Informação Acionistas
Dave Marver 2,87 %
EQT Life Sciences Group B.V. 10.84 %
Gimv Investments H&C Netherlands 2016 B.V. 9,25 %
INKEF Capital B.V. 11,52 %
Invest-NL N.V. 3,14 %
Wellington Partners Nominee 7.58 %
Fonte: Onward Medical N.V. - Última atualização: 24 Sep 2024